Literature DB >> 16164394

Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention.

Angela E Bridy-Pappas1, Marya B Margolis, Kimberly J Center, Daniel J Isaacman.   

Abstract

Streptococcus pneumoniae causes significant morbidity and mortality. Children younger than 2 years and individuals older than 65 years experience the highest rates of pneumococcal disease. Efforts to treat pneumococcal disease have been complicated by increasing resistance to antimicrobials. Prevention efforts have included the pneumococcal polysaccharide vaccines and the pneumococcal conjugate vaccines, with use of these vaccines targeted to those at highest risk for disease. Information and background on S. pneumoniae and pneumococcal disease are provided. Vaccines targeted at this pathogen are reviewed, and the clinical trials that evaluated their safety, efficacy, and effectiveness are summarized. Also provided are recommendations for use of these vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16164394     DOI: 10.1592/phco.2005.25.9.1193

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  36 in total

1.  A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.

Authors:  Philippe Denoël; Mario T Philipp; Lara Doyle; Dale Martin; Georges Carletti; Jan T Poolman
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

2.  Using Inverse Problem Methods with Surveillance Data in Pneumococcal Vaccination.

Authors:  Karyn L Sutton; H T Banks; Carlos Castillo-Chavez
Journal:  Math Comput Model       Date:  2010-03-01

3.  Crystal structure of the Streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate.

Authors:  John L Andreassi; Patrick W Bilder; Matthew W Vetting; Steven L Roderick; Thomas S Leyh
Journal:  Protein Sci       Date:  2007-03-30       Impact factor: 6.725

4.  Pneumococcal Neuraminidase Substrates Identified through Comparative Proteomics Enabled by Chemoselective Labeling.

Authors:  Janet E McCombs; Jennifer J Kohler
Journal:  Bioconjug Chem       Date:  2016-03-22       Impact factor: 4.774

5.  Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease.

Authors:  Chiara Azzari; Maria Moriondo; Giuseppe Indolfi; Martina Cortimiglia; Clementina Canessa; Laura Becciolini; Francesca Lippi; Maurizio de Martino; Massimo Resti
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

6.  Identification of novel non-coding small RNAs from Streptococcus pneumoniae TIGR4 using high-resolution genome tiling arrays.

Authors:  Ranjit Kumar; Pratik Shah; Edwin Swiatlo; Shane C Burgess; Mark L Lawrence; Bindu Nanduri
Journal:  BMC Genomics       Date:  2010-06-03       Impact factor: 3.969

Review 7.  A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens.

Authors:  Calvin C Daniels; P David Rogers; Chasity M Shelton
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

8.  In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from cocolonized versus noncocolonized children.

Authors:  Gili Regev-Yochay; Richard Malley; Ethan Rubinstein; Meir Raz; Ron Dagan; Marc Lipsitch
Journal:  J Clin Microbiol       Date:  2007-11-26       Impact factor: 5.948

9.  The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.

Authors:  Mark I Garvey; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

10.  Evidence from multiplex molecular assays for complex multipathogen interactions in acute respiratory infections.

Authors:  John D Brunstein; Christy L Cline; Steven McKinney; Eva Thomas
Journal:  J Clin Microbiol       Date:  2007-10-31       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.